Video

Dr Aimee Tharaldson on the Interest in Developing Orphan Drugs

Orphan medications are gaining a lot of focus from manufacturers, Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts, said at the Academy of Managed Care Pharmacy's 27th Annual Meeting & Expo in San Diego, April 7-10.

Orphan medications are gaining a lot of focus from manufacturers, Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts, said at the Academy of Managed Care Pharmacy's 27th Annual Meeting & Expo in San Diego, April 7-10.

These drugs treat populations of less than 200,000 patients, but manufacturers are given financial incentives to develop orphan medications and as a result in 2014, 75% of specialt drug approvals were for orphan drugs.

"These medications cost hundreds of thousands of dollars a year and oftetimes about 30% of orphan medications become blockbuster medications," Dr Tharaldson said.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
David J. Maron, MD, FASPC, Stanford University School of Medicine
Karen Vo talks about antibullying campaigns and pediatric patients with derm conditions
Hira Ghani, DO, discusses underdiagnosed skin conditions in children
Rebecca Chacko, MD.
Dr María Díez Campelo
Dr María Díez Campelo
Dr María Díez Campelo
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo